TNFRSF11A and osteosarcoma: Therefore, diosmetin, to some extent, exerts anti-osteosarcoma effects partly via signaling pathways (such as Wnt and RANKL/RANK), in addition to dramatically inhibiting the activation of STAT3/c-Myc signaling pathway.